Valuation: Indivior Pharmaceuticals, Inc.

Capitalization 4.59B 3.98B 3.65B 3.44B 6.39B 435B 6.51B 43.38B 16.87B 211B 17.22B 16.84B 735B P/E ratio 2026 *
11.8x
P/E ratio 2027 * 10.9x
Enterprise value 4.64B 4.03B 3.69B 3.48B 6.47B 441B 6.59B 43.9B 17.07B 214B 17.42B 17.04B 744B EV / Sales 2026 *
3.69x
EV / Sales 2027 * 3.25x
Free-Float
97.76%
Yield 2026 *
-
Yield 2027 * -
1 day+0.44%
1 week+4.43%
Current month+4.43%
1 month-7.38%
3 months+16.56%
6 months+7.10%
Current year+4.84%
1 week 32.41
Extreme 32.41
38.52
1 month 32.41
Extreme 32.41
40.05
Current year 27.68
Extreme 27.68
41
1 year 13.42
Extreme 13.42
41
3 years 7.33
Extreme 7.33
41
5 years 7.33
Extreme 7.33
41
10 years 1.75
Extreme 1.75
41
Date Insider Type Main position Quantity % Market Cap.
05-13Free

Director

6,518 0.0053%
05-13Free

Director

6,518 0.0053%
05-13Free

Director

6,518 0.0053%
Change 5d. change 1-year change 3-years change Capi.($)
+0.44%+4.43%+167.34%+83.49% 4.59B
+0.55%+2.39%+46.96%+155.36% 1,009B
+2.02%+3.30%+50.15%+47.16% 560B
+1.02%+4.37%+19.70%+67.78% 401B
+0.77%-0.67%+22.19%+12.23% 328B
+2.24%+0.41%+29.51%+17.50% 288B
+1.85%+0.14%+22.04%+30.54% 272B
+4.43%-3.11%-40.46%-47.48% 194B
+1.15%+3.80%+20.41%+58.02% 189B
-0.02%-3.92%+14.85%+69.50% 160B
Average +1.44%+1.47%+35.27%+49.41% 340.6B
Weighted average by Cap. +1.34%+1.95%+30.62%+70.75%

Financials

2026 *2027 *
Net sales 1.26B 1.09B 1B 943M 1.75B 119B 1.79B 11.9B 4.63B 57.92B 4.72B 4.62B 202B 1.29B 1.12B 1.03B 965M 1.79B 122B 1.83B 12.18B 4.74B 59.27B 4.83B 4.73B 206B
Net income 414M 360M 330M 311M 577M 39.35B 588M 3.92B 1.52B 19.08B 1.56B 1.52B 66.44B 455M 395M 362M 341M 634M 43.19B 646M 4.3B 1.67B 20.94B 1.71B 1.67B 72.92B
Net Debt 54.5M 47.32M 43.39M 40.86M 75.93M 5.17B 77.36M 516M 201M 2.51B 205M 200M 8.74B -403M -350M -321M -302M -562M -38.3B -573M -3.82B -1.48B -18.57B -1.51B -1.48B -64.66B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
833
Date Price Change Volume
05/06/26 37.62 $ +0.44% 1,586,982
04/06/26 37.45 $ +5.70% 1,911,176
03/06/26 35.43 $ +5.10% 1,535,384
02/06/26 33.71 $ -3.35% 2,917,607
01/06/26 34.88 $ -3.16% 2,069,191
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
37.62USD
Average target price
51.50USD
Spread / Average Target
+36.91%

Quarterly revenue - Rate of surprise